Primerica

PRI · NYSE

$284.66+$3.82 (+1.36%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $280.84

PRI analyst rating

HoldConsensus of 5 analysts over the last 12 months. 20% rate it a buy.

Strong buy0
Buy1
Hold4
Underperform0
Sell0

12-month price target · 7 analysts

Average $323.34 (+13.6% upside)

Low: $278.76
Now: $284.66
High: $378.00

Upgrades and downgrades

The latest rating actions, newest first

PRI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Keefe, Bruyette & Woods	Oct 9, 2026	Maintains	Market Perform	$335.00 → $330.00	71%
Truist Securities	Aug 27, 2026	Downgrade	Buy → Hold	$370.00 → $320.00	68%
Morgan Stanley	Aug 24, 2026	Maintains	Equal-Weight	$291.00 → $316.00	49%
Keefe, Bruyette & Woods	Aug 11, 2026	Maintains	Market Perform	$323.00 → $335.00	71%
TD Cowen	Jul 22, 2026	Maintains	Buy	$322.00 → $360.00	54%
Keefe, Bruyette & Woods	Jul 13, 2026	Maintains	Market Perform	$305.00 → $323.00	71%
Jefferies	Jul 10, 2026	Maintains	Hold	$266.00 → $268.00	76%
Morgan Stanley	May 21, 2026	Maintains	Equal-Weight	$280.00 → $291.00	49%
Keefe, Bruyette & Woods	May 13, 2026	Maintains	Market Perform	$290.00 → $305.00	71%
Keefe, Bruyette & Woods	Mar 26, 2026	Initiates	Market Perform	$290.00	71%

The case for and against

Updated Jan 26, 2025

Bull case

Primerica has demonstrated robust growth across several key metrics, notably a 4% increase in new policies issued, reaching 100,768, and a significant 29% surge in Investment and Savings Products (ISP) sales to $3.1 billion. The company's Term Life segment revenues for the second quarter reached $427 million, which aligns well with projections, contributing to a total operating revenue of $753 million that exceeded both internal forecasts and consensus estimates. Furthermore, the expansion of the salesforce by 6% year-over-year, alongside an expected 15% growth in ISP sales for 2024, suggests a positive trajectory for the company's future performance.

Bear case

Primerica Inc faces several risks that contribute to a negative outlook on its stock, including potential slow growth in new recruitment which could adversely affect its overall salesforce, alongside an increased mortality rate in its Life segment that may hinder profitability. The company reported a significant $254 million write-off of goodwill and intangibles related to its Senior Health operations, highlighting potential underlying issues. Additionally, Primerica's price-to-earnings ratio appears elevated compared to its peers in the life insurance sector, further raising concerns about its valuation amidst an uncertain financial environment.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.